HEPATOLOGY Flashcards

1
Q

Alcoholic Hepatitis - Definition

A

Inflammatory liver injury caused by chronic heavy intake of alcohol.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Alcoholic Hepatitis - Aetiology

A

One of the three forms of liver disease caused by excessive intake of alcohol, a spectrum that ranges from alcoholic fatty liver (steatosis) to alcoholic hepatitis and chronic cirrhosis. In alcoholic hepatitis, the liver histopathology shows centrilobular ballooning degeneration and necrosis of hepatocytes, steatosis, neutrophilic inflammation, cholestasis, Mallory hyaline inclusions (eosinophilic intracytoplasmic aggregates of cytokeratin inter- mediate filaments) and giant mitochondria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Alcoholic Hepatitis - History

A

May remain asymptomatic and undetected unless they present for other reasons. May be mild illness with nausea, malaise, epigastric or right hypochondrial pain and a low-grade fever.
May be more severe with jaundice, abdominal discomfort or swelling, swollen ankles or GI bleeding. Women tend to present with more florid illness than men. There is a history of heavy alcohol intake (􏰁15–20 years of excessive intake necessary for development of alcoholic hepatitis). There may be trigger events (e.g. aspiration pneumonia or injury).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Alcoholic Hepatitis - Examination

A

Signs of alcohol excess: Malnourished, palmar erythema, Dupuytren’s contracture, facial telangiectasia, parotid enlargement, spider naevi, gynaecomastia, testicular atrophy, hepatomegaly, easy bruising.
Signs of severe alcoholic hepatitis: Febrile (50% of patients), tachycardia, jaundice (>50% of patients), bruising, encephalopathy (e.g. hepatic foetor, liver flap, drowsiness, unable to copy a five-pointed star, disoriented), ascites (30–60% of patients), hepato- megaly (liver is usually mild–moderately enlarged and may be tender on palpation), splenomegaly.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Alcoholic Hepatitis - Investigations

A

Blood: FBC: low Hb, high MCV, high WCC, low platelets. LFT (high transminases, high bilirubin, low albumin, high AlkPhos, high GGT). U&E: Urea and K+ levels tend to be low, unless significant renal impairment. Clotting: Prolonged PT is a sensitive marker of significant liver damage.
Ultrasound scan: For other causes of liver impairment (e.g. malignancies).
Upper GI endoscopy: To investigate for varices.
Liver biopsy: Percutaneous or transjugular (in the presence of coagulopathy) may be helpful
to distinguish from other causes of hepatitis.
Electroencephalogram: For slow-wave activity indicative of encephalopathy.
MANAGEMENT

Acute: Thiamine, Vitamin C and other multivitamins (initially parenterally). Monitor and correct K+ , Mg2+ and glucose abnormalities. Ensure adequate urine output. Treat encephalopathy with oral lactulose and phosphate enemas. Ascites is managed by diuretics (spironolactone with or without frusemide (furosemide)) or therapeutic para- centesis. Glypressin and N-acetylcysteine for hepatorenal syndrome.
Nutrition: Nutritional support with oral or nasogastric feeding is important with increased caloric intake. Protein restriction should be avoided unless the patient is encephalopathic. Total enteral nutrition may also be considered as this improves mortality rate. Nutritional supplementation and vitamins (B group, thiamine, folic acid) should be started parenterally initially and then continued orally after.
Steroid therapy: Meta-analyses show that steroids reduce short-term mortality for severe alcoholic hepatitis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cirrhosis - Definition

A

End-stage of chronic liver damage with replacement of normal liver archi- tecture with diffuse fibrosis and nodules of regenerating hepatocytes. Decompensated when there are complications such as ascites, jaundice, encephalopathy or GI bleeding (see Liver failure).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cirrhosis - Aetiology

A

Chronic alcohol misuse: Most common UK cause.
Chronic viral hepatitis: Hepatitis B/C are the most common causes worldwide. Autoimmune hepatitis.
Drugs: e.g. methotrexate, hepatotoxic drugs.
Inherited: a1-Antitrypsin deficiency, haemochromatosis, Wilson’s disease, galactosaemia,
cystic fibrosis.
Vascular: Budd–Chiari syndrome or hepatic venous congestion.
Chronic biliary diseases: Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC),
biliary atresia.
Cryptogenic: In 5–10%.
Non-alcoholic steatohepatitis (NASH) increased risk of developing cirrhosis. NASH is associated
with obesity, diabetes, total parenteral nutrition, short bowel syndromes, hyperlipidaemia
and drugs, e.g. amiodarone, tamoxifen.
Decompensation can be precipitated by infection, GI bleeding, constipation, high-protein
meal, electrolyte imbalances, alcohol and drugs, tumour development or portal vein thrombosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cirrhosis - History

A

Early non-specific symptoms: Anorexia, nausea, fatigue, weakness, weight loss. Symptoms caused by lowe liver synthetic function: Easy bruising, abdominal swelling, ankle
oedema.
Reduced detoxification function: Jaundice, personality change, altered sleep pattern,
amenorrhoea.
Portal hypertension: Abdominal swelling, haematemesis, PR bleeding or melaena.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cirrhosis - Examination

A

Stigmata of chronic liver disease (ABCDE): Asterixis (‘liver flap’). Bruises. Clubbing. Dupuytren’s contracture. Erythema (palmar). Jaundice, gynaecomastia, leukonychia, parotid enlargement, spider naevi, scratch marks, ascites (‘shifting dullness’ and fluid thrill), enlarged liver (shrunken and small in later stage), testicular atrophy, caput medusae (dilated superficial abdominal veins), splenomegaly (indicating portal hypertension).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cirrhosis - Investigations

A

Blood: FBC: low Hb, low platelets as a result of hypersplenism. LFTs: May be normal or often high transaminases, AlkPhos, GGT, bilirubin, low albumin. Clotting: Prolonged PT (low synthesis of clotting factors). Serum AFP: High In chronic liver disease, but high levels may suggest hepatocellular carcinoma.
Other investigations: To determine the cause, e.g. viral serology (HBsAg, HBsAb, HCV ab), a1-antitrypsin, caeruloplasmin (Wilson’s disease), iron studies: serum ferritin, iron, total iron binding capacity (haemochromatosis), antimitochondrial antibody (PBC), antinuclear antibodies (ANA), SMA (autoimmune hepatitis).
Ascitic tap: Microscopy, culture and sensitivity, biochemistry (protein, albumin, glucose, amylase) and cytology. If neutrophils >250/mm3, this indicates spontaneous bacterial peritonitis (SBP).
Liver biopsy: Percutaneous or transjugular if clotting deranged or ascites present. Histo- pathology: Periportal fibrosis, loss of normal liver architecture and nodular appearance. Grade refers to the assessment of degree of inflammation, whereas stage refers to the degree of architectural distortion, ranging from mild portal fibrosis to cirrhosis.Imaging: Ultrasound, CT or MRI (to detect complications of cirrhosis such as ascites, hepatocellular carcinoma, and hepatic or portal vein thrombosis, to exclude biliary obstruction), MRCP (if PSC suspected).
Endoscopy: Examine for varices, portal hypertensive gastropathy.
Child–Pugh grading: Class A is score 5–6, Class B is score 7–9, Class C is score 10–15.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cirrhosis - Management

A

Treat the cause if possible, avoid alcohol, sedatives, opiates, NSAIDs and drugs that affect the liver. Nutrition is very important and if intake is poor, dietitian review and enteral supplements should be given; nasogastric feeding may be indicated.
Treat the complications:
Encephalopathy: Treat infections. Exclude a GI bleed. Lactulose, phosphate enemas and avoid sedation.
Ascites: Diuretics (spironolactone􏰅furosemide), dietary sodium restriction (88meq or 2g/day), therapeutic paracentesis (with human albumin replacement IV). Monitor weight daily. Fluid restriction in patients with plasma sodium <120mmol/L. Avoid alcohol and NSAIDs.
SBP: Antibiotic treatment (e.g. cefuroxime and metronidazole), prophylaxis against recurrent SBP with ciprofloxacin.
Surgical: Consider insertion of TIPS to relieve portal hypertension (if recurrent variceal bleeds or diuretic-resistant ascites) although it may precipitate encephalopathy. Liver transplantation is the only curative measure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Autoimmune Hepatitis - Definition

A

Chronic hepatitis of unknown aetiology, characterized by autoimmune features, hyperglobulinaemia and the presence of circulating autoantibodies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Autoimmune Hepatitis - Aetiology

A
A E T I O L O G Y In a genetically predisposed individual, an environmental agent (e.g. viruses or drugs) may lead to hepatocyte expression of HLA antigens which then become the focus of a principally T-cell-mediated autoimmune attack. The raised titres of ANA, ASM and anti-liver/kidney microsomes (anti-LKM) are not thought to directly injure the liver. The chronic inflammatory changes are similar to those seen in chronic viral hepatitis with lymphoid infiltration of the portal tracts and hepatocyte necrosis, leading to fibrosis and, eventually, cirrhosis. Two major forms:
Type I (classic): ANA, anti-smooth muscle antibodies (ASMA), anti-actin antibodies (AAA), anti-soluble liver antigen (anti-SLA).
Type 2: Antibodies to liver/kidney microsomes (ALKM-1, directed at an epitope of CYP2D6), antibodies to a liver cytosol antigen (ALC-1).
Patients with variant forms of autoimmune hepatitis have clinical and serologic findings of autoimmune hepatitis plus features of PBC or PSC.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Autoimmune Hepatitis - History

A

May be asymptomatic and discovered incidentally by abnormal LFT. Insidious onset: Malaise, fatigue, anorexia, weight loss, nausea, jaundice, amenorrhoea,
epistaxis.
Acute hepatitis (25%): Fever, anorexia, jaundice, nausea, vomiting, diarrhoea, RUQ pain.
Some may also present with serum sickness (e.g. arthralgia, polyarthritis, maculopapular
rash).
May be associated with keratoconjuctivitis sicca.
Personal or family history of autoimmune disease, e.g. type 1 diabetes mellitus and vitiligo.
It is important to take a full history to rule out other potential causes of liver disease (e.g. alcohol, drugs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Autoimmune Hepatitis - Examination

A

Stigmata of chronic liver disease, e.g. spider naevi (see Cirrhosis). Ascites, oedema and encephalopathy are late features.
Cushingoid features (e.g. rounded face, cutaneous striae, acne, hirsuitism) may be present
even before the administration of steroids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Autoimmune Hepatitis - Investigations

A
Blood: LFT: very high AST and ALT, very high GGT, high AlkPhos, high bilirubin, low albumin in severe disease. Clotting: high PT in severe disease. FBC: Mild low Hb, also low platelets and WCC from hypersplenism if portal hypertension present.
Hypergammaglobulinaemia is typical (polyclonal gammopathy) with the presence of ANA, ASMA or anti-LKM autoantibodies.
Liver biopsy: Needed to establish the diagnosis. Shows interface hepatitis or cirrhosis. Other investigations: To rule out other causes of liver disease, e.g. viral serology (hepatitis B and C) caeruloplasmin and urinary copper (Wilson’s disease), ferritin and transferrin saturation (haemochromatosis), a1-antitrypsin (a1-antitrypsin deficiency) and antimito-
chondrial antibodies (PBC).
Ultrasound, CT or MRI of liver and abdomen: To visualize structural lesions. ERCP: To rule out PSC.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Autoimmune Hepatitis - Management

A

Indications: Aminotransferases more than 10 times the upper limit of normal, symptomatic, histology: significant interface hepatitis, bridging necrosis or multiacinar necrosis.
Immunosuppression with steroids (e.g. prednisolone), followed by maintenance treatment with gradual reduction in dose (treatment is often long term). Azathioprine or 6-mercaptopurine (6-MP) may be used in the maintenance phase as a steroid-sparing agent with frequent monitoring of LFT and FBC. (Test for TPMT1 activity before starting azathioprine or 6-MP.)
Monitor: Ultrasound and a-fetoprotein level every 6–12 months in patients with cirrhosis (to detect hepatocellular carcinoma). Repeat liver biopsies for evidence of disease progres- sion (<2 years).
Hepatitis A and B vaccinations.
Liver transplant: For patients who are refractory to or intolerant of immunosuppressive
therapy and those with end-stage disease.

18
Q

Hepatitis Viral A and E - Definition

A

Hepatitis caused by infection with the RNA viruses, hepatitis A (HAV) or hepatitis E virus (HEV), that follow an acute course without progression to chronic carriage.

19
Q

Hepatitis Viral A and E - Aetiology

A

HAV is a picornavirus and HEV is a calicivirus. Both are small non-enveloped single-stranded linear RNA viruses of 􏰁7500 nucleotides, with transmission by the faecal–oral route.
Both viruses replicate in hepatocytes and are secreted into bile. Liver inflammation and hepatocyte necrosis is caused by the immune response, with targeting of infected cells by CD8+ T cells and natural killer cells. Histology shows inflammatory cell infiltration (neutrophils, macrophages, eosinophils and lymphocytes) of the portal tracts, zone 3 necrosis and bile duct proliferation.

20
Q

Hepatitis Viral A and E - History

A

Incubation period for HAV or HEV is 3–6 weeks.
Prodromal period: Malaise, anorexia (distaste for cigarettes in smokers), fever, nausea and
vomiting.
Hepatitis: Prodrome followed by dark urine, pale stools and jaundice lasting 􏰁3 weeks.
Occasionally, itching and jaundice last several weeks in HAV infection (owing to cholestatic hepatitis).

21
Q

Hepatitis Viral A and E - Examination

A

Pyrexia, jaundice, tender hepatomegaly, spleen may be palpable (20%). Absence of stigmata of chronic liver disease, although a few spider naevi may appear, transiently.

22
Q

Hepatitis Viral A and E - Investigations

A

Blood: LFT ( very high AST and ALT, high bilirubin, high AlkPhos), high ESR. In severe cases, low albumin an high platelets.
Viral serology:
Hepatitis A: Anti-HAV IgM (during acute illness, disappearing after 3–5 months), anti-HAV IgG (recovery phase and lifelong persistence).
Hepatitis E: Anti-HEV IgM (“ 1–4 weeks after onset of illness), anti-HEV IgG. Hepatitis B and C viral serology is also necessary to rule out these infections.
Urinalysis: Positive for bilirubin, high urobilinogen.

23
Q

Hepatitis Viral A and E - Management

A

No specific management. Bed rest and symptomatic treatment (e.g. antipyretics, antiemetics). Colestyramine for severe pruritus.
Prevention and control:
Public health: Safe water, sanitation, food hygiene standards. Both are notifiable diseases. Personal hygiene and sensible dietary precautions when travelling.
Immunization (HAV only): Passive immunization with IM human immunoglobulin is only effective for a short period. Active immunization with attenuated HAV vaccine offers safe and effective immunity for those travelling to endemic areas, high-risk individuals (e.g. residents of institutions).

24
Q

Hepatitis Viral B and D - Definition

A

Hepatitis caused by infection with hepatitis B virus (HBV), which may follow an acute or chronic (defined as viraemia and hepatic inflammation continuing >6 months) course.
Hepatitis D virus (HDV), a defective virus, may only co-infect with HBV or superinfect persons who are already carriers of HBV.

25
Q

Hepatitis Viral B and D - Aetiology

A

HBV is an enveloped, partially double-stranded DNA virus. Transmission is by sexual contact, blood and vertical transmission. Various viral proteins are produced, including core antigen (HBcAg), surface antigen (HBsAg) and e antigen (HBeAg). HBeAg is a marker of high infectivity.
HDV is a single-stranded RNA virus coated with HBsAg.
Antibody- and cell-mediated immune responses to viral replication lead to liver inflammation
and hepatocyte necrosis. Histology can be variable, from mild to severe inflammation and changes of cirrhosis.

26
Q

Hepatitis Viral B and D - Associations/risk factors

A

Hepatitis B infection is associated with IV drug abuse, unscreened blood and blood products, infants of HbeAg-positive mothers and sexual contact with HBV carriers. Risk of persistant HBV infection varies with age, with younger individuals, especially babies, more likely to develop chronic carriage. Genetic factors are associated with “ rates of viral clearance.

27
Q

Hepatitis Viral B and D - History

A

ncubation period 3–6 months; 1- to 2-week prodrome of malaise, headache, anorexia, nausea, vomiting, diarrhoea and RUQ pain.
May experience serum-sickness-type illness (e.g. fever, arthralgia, polyarthritis, urticaria,
maculopapular rash).
Jaundice then develops with dark urine and pale stools.
Recovery is usual within 4–8 weeks. One per cent may develop fulminant liver failure. Chronic carriage may be diagnosed after routine LFT testing or if cirrhosis or decompensation
develops.

28
Q

Hepatitis Viral B and D - Examination

A

Acute: Jaundice, pyrexia, tender hepatomegaly, splenomegaly and cervical lymphadenop- athy in 10–20%. Occasionally, urticaria/maculopapular rash.
Chronic: May have no findings; signs of chronic liver disease or decompensation.

29
Q

Hepatitis Viral B and D - Investigations

A

Viral serology:
Acute HBV: HbsAg positive, IgM anti-HbcAg.
Chronic HBV: HbsAg positive, IgG anti-HBcAg, HbeAg positive or negative (latter in precore
mutant variant).
HBV cleared or immunity: Anti-HBsAg positive, IgG anti-HBcAg.
HDV infection: Detected by IgM or IgG against HDV.
PCR: For detection of HBV DNA is the most sensitive measure of ongoing viral
replication.
LFT: very high AST and ALT. high Bilirubin. high AlkPhos.
Clotting: high PT in severe disease.
Liver biopsy: Percutaneous, or transjugular if clotting is deranged or ascites is present.

30
Q

Hepatitis Viral B and D - Management

A

Prevention: Blood screening, instrument sterilization, safe sex.

Passive immunization: Hepatitis B immunoglobulin (HBIG) following acute exposure and to neonates born to HbeAg-positive mothers (in addition to active immunization).
Active immunization: Recombinant HbsAg vaccine for individuals at risk and neonates born to HBV-positive mothers. Immunization against HBV protects against HDV.
Acute HBV hepatitis: Symptomatic treatment with bed rest, antiemetics, antipyretics and cholestyramine for pruritus. Notification to the consultant in communicable disease control.
Chronic HBV:
Indications for treatment with antivirals: HbeAg-positive or HbeAg-negative chronic
hepatitis (depending on ALT and HBV DNA levels), compensated cirrhosis and HBV DNA
>2,000 IU/mL, decompensated cirrhosis and detectable HBV DNA by PCR.
Patients may be treated with interferon alpha (standard or pegylated, which has “ half-life), or nucleos/tide analogues (adefovir, entecavir, telbivudine, tenofovir, lamivudine). The role
of lamivudine as primary therapy has diminished due to high rates of drug resistance. Interferon alpha is a cytokine which augments natural antiviral mechanisms. Side-effects include flu-like symptoms, fever, chills, myalgia, headaches, bone marrow suppression
and depression, necessitating discontinuation in 5–10% of patients.



31
Q

Viral Hepatitis C - Definition

A

Hepatitis caused by infection with hepatitis C virus (HCV), often following a chronic course (80% cases).

32
Q

Viral Hepatitis C - Aetiology

A

HCV is a small, enveloped, single-stranded RNA virus, fidelity of replication is poor and mutation rates are high = different HCV genotypes, even one patient many quasi-species present.

Transmission: Parenteral route. At risk - recipients of blood and blood products prior to blood screening, IV drug users, non-sterile acupuncture and tattooing, those on haemodialysis and health care workers.

Sexual and vertical trans- mission uncommon (1–5%, higher risk in those co-infected with HIV).

Pathology/Pathogenesis: Although HCV is hepatotropic, it is not thought that the virus is directly hepatotoxic, rather that the humoral and cell-mediated response leads to hepatic inflammation and necrosis. On liver biopsy, chronic hepatitis is seen and a characteristic feature is lymphoid follicles in the portal tracts. Fatty change is also common and features of cirrhosis may be present.

33
Q

Viral Hepatitis C - History

A

90% acute infections are asymptomatic with <10% becoming jaundiced with a mild ‘flu-like’ illness.
May be diagnosed after incidental abnormal LFT or in older individuals with complications of cirrhosis.

34
Q

Viral Hepatitis C - Examination

A

There may be no signs or may be signs of chronic liver disease in long-standing infection. Less common extra-hepatic manifestations include:
. skin rash, caused by mixed cryoglobulinaemia causing a small-vessel vasculitis; and
. renal dysfunction, caused by glomerulonephritis.

35
Q

Viral Hepatitis C - Investigations

A

Blood:
HCV serology: Anti-HCV antibodies, either IgM (acute) or IgG (past exposure or chronic). Reverse-transcriptase PCR: Detection and genotyping of HCV RNA. Used to confirm antibody
testing; also recommended in patients with clinically suspected HCV infection but
negative serology.
LFT: Acute infection causes high AST and ALT, mild high bilirubin. Chronic infection causes 2–8 times
elevation of AST and ALT, often fluctuating over time. Sometimes normal.
Liver biopsy: To assess degree of inflammation and liver damage as transaminase levels bear little correlation to histological changes. Also useful in diagnosing cirrhosis as patients
with cirrhosis will require monitoring for hepatocellular carcinoma.

36
Q

Viral Hepatitis C - Management

A

Prevention: Screening of blood, blood products and organ donors, needle exchange schemes for IV drug abusers, instrument sterilization. No vaccine available at present.
Medical:
Acute: No specific management and mainly supportive (e.g. antipyretics, antiemetics,
cholestyramine). Specific antiviral treatment can be delayed for 3–6 months.

Chronic: Combined treatment with pegylated interferon-a (cytokine which augments natural antiviral mechanisms) and ribavirin (guanosine nucleotide analogue) is the treatment strategy of choice:
. HCV genotype 1 or 4: 24–48 weeks
. HCV genotype 2 or 3: 12–24 weeks
Monitoring of HCV viral load is recommended after 12 weeks of treatment to determine efficacy of treatment. Regular ultrasound of liver may be necessary if the patient has cirrhosis.

37
Q

Hepatocellular carcinoma - Definition

A

Primary malignancy of hepatocytes, usually occurring in a cirrhotic liver.

38
Q

Aetiology

A

Chronic liver damage (e.g. alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disease),
. metabolic disease (e.g. haemochromatosis), and
. aflatoxins (Aspergillus flavus fungal toxin found on stored grains or biological
weapons).

39
Q

History

A

Symptoms of malignancy: Malaise, weight loss, loss of appetite.
Symptoms of chronic liver disease: Abdominal distension, jaundice.
History of carcinogen exposure: High alcohol intake, Hepatitis B or C, aflatoxins.

40
Q

Examination

A

Signs of malignancy: Cachexia, lymphadenopathy.
Hepatomegaly: Nodular (but may be smooth). Deep palpation may elicit tenderness. There
may be bruit heard over the liver.
Signs of chronic liver disease: Jaundice, ascites

41
Q

Investigations

A

Blood: high AFP (tumour marker with high sensitivity), Vitamin B12-binding protein is a marker of fibrolamellar hepatocellular carcinoma. LFT has poor specificity and sensitivity but may show biliary obstruction.
Abdominal ultrasound: Not sensitive for tumours <1 cm.
Duplex scan of liver: May be used to demonstrate large vessel invasion (e.g. into hepatic or
portal veins).
CT (thorax, abdomen, pelvis): To define structural lesion and spread.
Hepatic angiography: Using lipiodol (an iodized oil).
Liver biopsy: Confirms histology of tumour but there is small risk of tumour seeding along
biopsy tract.
Staging: CXR, CT (thorax, abdomen, pelvis), radionuclide bone scan. Screening: AFP and abdominal ultrasound in at-risk individuals.

42
Q

Management

A

Surgery: Surgical resection possible in <10% (40–50% of fibrolamellar hepatocellular carcinoma), tumours must be small and localized to a single lobe.

Liver transplantation may be considered if disease is small and localized to the liver.

Local therapy: Percutaneous ethanol injection, cryoablation and radiofrequency ablation are approaches used.

Interventional radiography (e.g. embolization): Using microspheres, chemotherapy agents or radio-labelled lipiodol. 
Usually palliative.

Chemotherapy: Tumours tend to be chemoresistant to traditional agents (only 10% respond to doxorubicin, cisplatin and carboplatin).

Biological agents: Bevacizumab (anti-angiogenic monoclonal) can be used in adjunct to traditional chemotherapeutic agents.

Tyrosine kinase inhibitors (Sorafenib and Sunitinib): Small molecules which inhibit cellular signalling of a number of growth factor pathways. Some effectiveness in prolonging survival.